Arnivas 100 Tablet

Arnivas 100 49 mg + 51 mg Tablet সম্পর্কে

বাংলাদেশে Arnivas 100 49 mg + 51 mg Tablet ট্যাবলেট হিসেবে পাওয়া যায়; এতে Sacubitril + Valsartan আছে (৪৯ mg + ৫১ mg)। Sacubitril + Valsartan-এর অন্য ব্র্যান্ডগুলো এই পাতায় কম দাম থেকে সাজানো আছে, দাম তুলনা করতে পারবেন। এই ব্র্যান্ডের প্রস্তুতকারক Opsonin Pharma Limited। এই তথ্য শুধু জানার জন্য; ঔষধ সবসময় ডাক্তারের পরামর্শ অনুযায়ী খাবেন, মাত্রা বা ব্র্যান্ড নিয়ে প্রশ্ন থাকলে ফার্মাসিস্টকে জিজ্ঞেস করুন।

Sacubitril + Valsartan-এর ২৫টি ব্র্যান্ড বাংলাদেশে তালিকাভুক্ত। সবচেয়ে কম দাম Arnis 24 mg+26 mg Tablet-এর, প্রতি ইউনিট ৳ ৩৫.০০।

Arnivas 100 49 mg + 51 mg Tablet কী?

Made by Opsonin Pharma Limited, Arnivas 100 is a tablet whose active ingredient is Sacubitril + Valsartan. Together, they help reduce the risk of death and hospitalization from heart failure in adults with reduced ejection fraction, and treat symptoms in children aged one year and older. Regular monitoring of blood pressure, kidney function, and potassium is needed during treatment. Whether it suits you is a decision for your doctor.

Arnivas 100-এর ব্যবহার

Arnivas 100 is used to lower the risk of death from heart problems and hospitalization in adults with long-term heart failure and a reduced pumping action of the heart. Arnivas 100 is used to treat chronic heart failure in adults when the heart does not pump well (reduced ejection fraction). It is a prescription medicine, and the doctor will confirm whether it is appropriate for the patient's condition. The doctor decides whether it is suitable, based on the patient's condition and other medicines being taken.

Arnivas 100 কীভাবে ব্যবহার করবেন

Arnivas 100 is taken by mouth as a tablet. Swallow the tablet with water. Tell your doctor about all other medicines you take, including ACE inhibitors, ARBs, aliskiren, potassium-sparing diuretics, NSAIDs and lithium, because interactions can occur. If you miss a dose, ask your doctor or pharmacist what to do.

Arnivas 100-এর পার্শ্বপ্রতিক্রিয়া

Do not ignore severe symptoms. Your doctor may adjust the dose or recommend tests to monitor your condition. Some people may experience these effects. Tell your doctor promptly if you notice swelling, difficulty breathing, or a big drop in blood pressure. Tell your doctor if you feel very dizzy or faint, or pass much less urine than usual.

সতর্কতা ও নিরাপত্তা

Do not take Arnivas 100 if you are allergic to any of its ingredients, if you have had angioedema after taking an ACE inhibitor or ARB, or if you have hereditary angioedema. Arnivas 100 must not be used by anyone with a history of angioedema related to an ACE inhibitor or ARB, or with hereditary angioedema. Pregnancy and breastfeeding: ask the doctor before use. Tell your doctor if you have kidney or liver problems, low blood pressure, or high potassium.

সাধারণ প্রশ্ন

Why is Arnivas 100 prescribed?

Arnivas 100 is used to lower the risk of death from heart problems and hospitalization in adults with long-term heart failure and a reduced pumping action of the heart. Arnivas 100 is used to treat chronic heart failure in adults when the heart does not pump well (reduced ejection fraction).

How is Arnivas 100 used?

Arnivas 100 is taken by mouth as a tablet. Swallow the tablet with water.

Can Arnivas 100 cause side effects?

Do not ignore severe symptoms. Your doctor may adjust the dose or recommend tests to monitor your condition.

Is Arnivas 100 safe for everyone?

Do not take Arnivas 100 if you are allergic to any of its ingredients, if you have had angioedema after taking an ACE inhibitor or ARB, or if you have hereditary angioedema. Arnivas 100 must not be used by anyone with a history of angioedema related to an ACE inhibitor or ARB, or with hereditary angioedema.

নির্দেশনা

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

This is indicated:
  • To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction.
  • For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
  • ... Read more
This is indicated:
  • To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction.
  • For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
  • This is usually administered in conjunction with other heart failure therapies, in place of an angiotensin-converting enzyme inhibitor (ACEi) or other ARB.

ফার্মাকোলজি

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

This tablet contains a neprilysin inhibitor, sacubitril, and an angiotensin receptor blocker, valsartan. This tablet inhibits neprilysin (neutral endopeptidase; NEP) via LBQ657, the active metabolite of the prodrug sacubitril, and blocks the angiotensin II type-1 (AT1 ) receptor via valsartan. The cardiovascular and renal effects of this tablet in heart failure patients are attributed to the increased levels of peptides that are degraded by neprilysin, such as natriuretic peptides, by LBQ657, and the simultaneous inhibition of the effects of angiotensin II by valsartan. Valsartan inhibits the effects of angiotensin II by selectively blocking the AT1 receptor, and also inhibits angiotensin II-dependent aldosterone release.

মাত্রা ও সেবনবিধি

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Adult Heart Failure: The recommended starting dose is 49/51 mg orally twice daily. Double the dose after 2 to 4 weeks to the target maintenance dose of 97/103 mg twice daily, as tolerated by the patient.

Reduce the starting dose to 24/26 mg twice daily for:
  • Patients not currently taking an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB) or previously taking a low dose of these agents.
  • Patients with severe renal impairment.
  • Patients with moderate hepatic impairment.
Pediatric Heart Failure: Refer to Table 1 for the recommended dose for pediatric patients aged one year and older. Take the recommended dose orally twice daily. Adjust pediatric patient doses every 2 weeks, as tolerated by the patient.

Recommended Dose Titration-

Pediatric Patients Less than 40 kg:
  • Starting: 1.6 mg/kg
  • Second: 2.3 mg/kg
  • Final: 3.1 mg/kg
Pediatric Patients At least 40 kg, less than 50 kg:
  • Starting: 24/26 mg
  • Second: 49/51 mg
  • Final: 49/51 mg
Pediatric Patients At least 50 kg:
  • Starting: 49/51 mg
  • Second: 72/78 mg
  • Final: 97/103 mg

ঔষধের মিথষ্ক্রিয়া

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Dual Blockade of the Renin-Angiotensin-Aldosterone System: Should not be used with an ACEi, aliskiren in patients with diabetes, and use with an ARB should be avoided.
Potassium-sparing Diuretics: Serum potassium level may be increased.
NSAIDs: Risk of renal impairment may be increased.
Lithium: Increased risk of lithium toxicity.

প্রতিনির্দেশনা

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

This combination is contraindicated:
  • In patients with hypersensitivity to any component
  • In patients with a history of angioedema related to previous ACE inhibitor or ARB therapy 
  • With concomitant use of ACE inhibitors. Do not administer within 36 hours of switching from or to an ACE inhibitor 
  • With concomitant use of aliskiren in patients with diabetes

পার্শ্ব প্রতিক্রিয়া

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

The most common side effects are Angioedema, Hypotension, Impaired Renal Function, Hyperkalemia, Cough, Dizziness.

গর্ভাবস্থায় ও স্তন্যদানকালে

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Pediatric Use: Safety and effectiveness have not been established in pediatric patients less than 1 year of age.

Geriatric Use: No relevant pharmacokinetic differences have been observed in elderly (>65 years) or very elderly (>75 years) patients compared to the overall population.
 
Hepatic Impairment: No dose adjustment is required when administering this tablet to patients with mild hepatic impairment (Child-Pugh A classification). This tablet is not recommended in patients with severe hepatic impairment, as no studies have been conducted in these patients.

Renal Impairment: No dose adjustment is required in patients with mild (eGFR 60 to 90 ml/min/1.73 m2) to moderate (eGFR 30 to 60 ml/min/1.73 m2) renal impairment. The recommended starting dose in patients with severe renal impairment (eGFR <30 ml/min/1.73 m2) is 24/26 mg twice daily.

সতর্কতা

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

This tablet may cause angioedema and must not be used in patients with a known history of angioedema related to previous ACEi or ARB therapy and in patients with hereditary angioedema.

This tablet lowers blood pressure and may cause symptomatic hypotension. Closely monitor serum creatinine, and down-titrate or interrupt this tablet in patients who develop a clinically significant decrease in renal function. In patients with renal artery stenosis, monitor renal function.

Monitor serum potassium periodically and treat appropriately, especially in patients with risk factors for hyperkalemia such as severe renal impairment, diabetes, hypoaldosteronism, or a high potassium diet. Dosage reduction or interruption of this tablet may be required.

মাত্রাধিক্যতা

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Limited data are available with regard to overdosage in human subjects with this tablet. In healthy volunteers, a single dose of this tablet 583 mg sacubitril/617 mg valsartan, and multiple doses of 437 mg sacubitril/463 mg valsartan (14 days) have been studied and were well tolerated. Hypotension is the most likely result of overdosage due to the blood-pressure-lowering effects of this tablet. Symptomatic treatment should be provided. This tablet is unlikely to be removed by hemodialysis because of high protein binding.

সংরক্ষণ

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Keep in a dry place and store below 30°C. Protect from moisture and keep out of the reach of children.

বিকল্প ব্র্যান্ড: Sacubitril + Valsartan

একই জেনেরিকের অন্য ব্র্যান্ড, কম দাম আগে।

Arnis Tablet

24 mg+26 mg

Sacubitril + Valsartan

Eskayef Pharmaceuticals Ltd.

৳ ৩৪.৩ ৳ ৩৫.০০ ২% ছাড় প্রতি ইউনিট

Covista 50 Tablet

24 mg + 26 mg

Sacubitril + Valsartan

Advanced Chemical Industries PLC

৳ ৪১.১৬ ৳ ৪২ ২% ছাড় প্রতি ইউনিট

Arnigen Tablet

24 mg+26 mg

Sacubitril + Valsartan

General Pharmaceuticals Ltd.

৳ ৪৪.১ ৳ ৪৫.০০ ২% ছাড় প্রতি ইউনিট

Arnivas Tablet

24 mg+26 mg

Sacubitril + Valsartan

Opsonin Pharma Ltd.

৳ ৪৪.১ ৳ ৪৫.০০ ২% ছাড় প্রতি ইউনিট

Valmor 50 Tablet

24 mg + 26 mg

Sacubitril + Valsartan

Square Pharmaceuticals PLC.

৳ ৪৪.১ ৳ ৪৫ ২% ছাড় প্রতি ইউনিট

Arnis Tablet

49 mg+51 mg

Sacubitril + Valsartan

Eskayef Pharmaceuticals Ltd.

৳ ৬৮.৬ ৳ ৭০.০০ ২% ছাড় প্রতি ইউনিট

Covista 100 Tablet

49 mg + 51 mg

Sacubitril + Valsartan

Advanced Chemical Industries PLC

৳ ৭৬.৪৪ ৳ ৭৮ ২% ছাড় প্রতি ইউনিট

Arnivas Tablet

49 mg+51 mg

Sacubitril + Valsartan

Opsonin Pharma Ltd.

৳ ৭৮.৪ ৳ ৮০.০০ ২% ছাড় প্রতি ইউনিট

Arnigen Tablet

49 mg+51 mg

Sacubitril + Valsartan

General Pharmaceuticals Ltd.

৳ ৮৩.৩ ৳ ৮৫.০০ ২% ছাড় প্রতি ইউনিট

Arnigen Tablet

97 mg+103 mg

Sacubitril + Valsartan

General Pharmaceuticals Ltd.

৳ ১১৭.৬ ৳ ১২০.০০ ২% ছাড় প্রতি ইউনিট

সব দেখুন ২৫ ব্র্যান্ড

ঔষধের তথ্য শুধু জানার জন্য, এটি চিকিৎসা পরামর্শ নয়। সবসময় ডাক্তারের প্রেসক্রিপশন মানুন এবং ফার্মাসিস্টের সাথে কথা বলুন।